Brief: Eagle Pharmaceuticals Reports Third Quarter 2021 Results
09/11/2021 11:51
Nov 9 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS REPORTS THIRD QUARTER 2021 RESULTS
* Q3 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.56
* Q3 LOSS PER SHARE $0.43
* Q3 REVENUE $39.9 MILLION
* EXPECT TO RECEIVE APPROVAL FOR ABBREVIATED NEW DRUG
APPLICATION
("ANDA") FOR VASOPRESSIN; DECEMBER 15, 2021 GDUFA DATE
Source text for Eikon: ID:nBw6BMxDna
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq